The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•6 April 2026•

1 min read

Actinium Pharmaceuticals to Present New Cancer Therapy Data at AACR 2026

Key Facts

1Actinium Pharmaceuticals will present new data for ATNM-400 and Actimab-A at the 2026 AACR Annual Meeting.

2ATNM-400 demonstrated broad pan-tumor efficacy across multiple solid tumor models.

Version History

1 additional source confirmed this story

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) has announced it will present new preclinical data for its targeted radiotherapy platform at the 2026 AACR Annual Meeting. The presentation will focus on the company's ATNM-400 and Actimab-A candidates, highlighting their potential in treating various cancers. Preclinical results for ATNM-400 demonstrated broad efficacy across several solid tumor models, showcasing the versatility of the Ac-225 platform. Additionally, Actimab-A revealed a novel mechanism of action that enhances the effectiveness of standard treatments for acute myeloid leukemia (AML). These findings underscore Actinium's commitment to expanding its radiotherapy applications for both hematologic and solid malignancies. Investors are closely watching these developments as positive preclinical data often serves as a catalyst for future clinical advancements.